Overview

Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)

Status:
Not yet recruiting

Trial end date:
2024-08-01

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to determine the feasibility of liver stereotactic body radiation therapy (SBRT) given in combination with systemic therapy (ipilimumab and nivolumab) in adults with metastatic melanoma with liver metastases who are at significant risk of not benefiting from systemic therapy alone.

Phase:

Phase 1

Details

Lead Sponsor:

University of Michigan Rogel Cancer Center

Treatments:

Ipilimumab
Nivolumab